Insights
Not AI news. Not vendor hype. Practical perspectives from working inside complex, compliance-driven workflows every day.
Manufacturers are pouring money into AI pilots while their scheduling runs on spreadsheets and tribal knowledge. The use cases with the fastest payback aren't the flashy ones.
Everyone's automating invoice coding. Almost nobody is building the compliance scaffolding that makes it stick. Here's the gap mid-market CFOs keep falling into.
Everyone's talking about AI-driven inventory automation. Most mid-market operators are still running on spreadsheets and gut feel. Here's the gap — and how to close it without blowing up your ops.
The FDA's finalizing AI guidance that demands explainability, transparency, and real-world monitoring — and most mid-market device makers aren't remotely ready. Here's what that actually means for your workflows.
MIT found that 95% of enterprise AI pilots deliver zero measurable ROI. For companies in medical device, financial services, or manufacturing, the failure rate isn't just a budget problem — it's a compliance and operational risk.
Manufacturers are moving AI out of the pilot lab and into operations. That's the good news. The hard part — integration, compliance, and change control — is just getting started.
Mid-market manufacturers keep buying AI tools and getting marginal results. The problem isn't the tools — it's that nobody connected them to anything that matters.
Most financial services firms are building AI governance programs that look good on paper and collapse under operational weight. Here's what actually works.
FDA easing oversight on lower-risk AI devices sounds like good news. For mid-market manufacturers, it's actually a trap if you haven't built the right internal scaffolding first.
FDA and EU regulators are locking in AI oversight frameworks for 2026. Most mid-market medical device companies aren't close to ready — and the gap isn't technical, it's operational.
The FDA's 2025 draft guidance on AI-enabled devices buried a major compliance shift inside a document that doesn't even say 'human factors' in the title. Here's what it actually means for your validation strategy.
The FDA just drew clearer lines around AI in medical devices. For mid-market operators, this isn't a compliance headache — it's a forcing function that separates serious AI programs from expensive experiments.
New posts go out when they're ready — no filler, no cadence for cadence's sake.
Get in Touch